Viking isn't a biotech that will need to take out a lot of debt or issue a lot of new shares to get its therapies out the door. Therefore, buying its stock won't leave you at as high of a risk of your ...

The company's latest presentation supports the idea that its lead program will make billions.

Viking Therapeutics reported updated, early-stage study results on its oral obesity drug candidate. Vertex Pharmaceuticals said the first patient with sickle cell disease was treated with Casgevy, its ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector. YouTuber MrBeast becomes the 8th ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Tesla stock is headed toward its sixth straight loss Monday and Wall Street is staying on the sidelines. Here's why.

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...